Dr. Laurence Klotz named to the Order of Canada
Sunnybrook urological oncologist, Dr. Laurence Klotz, has been named to the Order of Canada "for his contributions to the treatment of prostate cancer, notably for leading the adoption of Active Surveillance as a standard aspect of patient care". The award highlights his pioneering work in the approach of Active Surveillance with Selective Delayed Intervention — a term developed by him, with the emphasis on close monitoring for men with low-risk prostate cancer, with selective definitive intervention for those who are diagnosed higher risk over time.
Dr. Klotz, who is also a professor in the Department of Surgery at the University of Toronto, and a member of the Genitourinary Cancer Care team at Sunnybrook’s Odette Cancer Centre, continues to be a strong proponent of this approach and is widely considered to have been instrumental in its acceptance by the urological community worldwide.
This approach is now a standard option for the first management of men with localized, well-differentiated prostate cancer, and is seen as the treatment of choice for men with very low risk prostate cancer.
Findings from a 2010 Journal of Clinical Oncology-published study led by Dr. Klotz at Sunnybrook that followed 450 Canadian men with low-risk prostate cancer over 13 years, reported a resounding positive benefit. For patients managed with Active Surveillance with Selective Delayed Intervention, the 15-year prostate cancer actuarial survival was 95 per cent. Two thirds of patients avoided treatment entirely.
The concept of Active Surveillance with Selective Delayed Intervention is increasingly being adopted in other cancer sites, particularly in breast cancer for DCIS (ductal carcinoma in situ).
Full media release
DR. LAURENCE KLOTZ NAMED TO THE ORDER OF CANADA
Toronto, CANADA (December 26, 2014) –Sunnybrook urological oncologist, Dr. Laurence Klotz, has been named to the Order of Canada ‘for his contributions to the treatment of prostate cancer, notably for leading the adoption of Active Surveillance as a standard aspect of patient care’. The award highlights his pioneering work in the approach of Active Surveillance with Selective Delayed Intervention – a term developed by him, with the emphasis on close monitoring for men with low-risk prostate cancer, with selective definitive intervention for those who are diagnosed higher risk over time.
Dr. Klotz, who is also a professor in the Department of Surgery at the University of Toronto, and a member of the Genitourinary Cancer Care team at Sunnybrook’s Odette Cancer Centre, continues to be a strong proponent of this approach and is widely considered to have been instrumental in its acceptance by the urological community worldwide.
This approach is now a standard option for the first management of men with localized, well-differentiated prostate cancer, and is seen as the treatment of choice for men with very low risk prostate cancer.
Findings from a 2010 Journal of Clinical Oncology-published study led by Dr. Klotz at Sunnybrook that followed 450 Canadian men with low-risk prostate cancer over 13 years, reported a resounding positive benefit. For patients managed with Active Surveillance with Selective Delayed Intervention, the 15-year prostate cancer actuarial survival was 95 per cent. Two thirds of patients avoided treatment entirely.
The concept of Active Surveillance with Selective Delayed Intervention is increasingly being adopted in other cancer sites, particularly in breast cancer for DCIS (ductal carcinoma in situ).
For more information, please contact:
Natalie Chung-Sayers, 416.480-4040
